Eortc MoBilE Device (EMBED)

NCT07711080 | Not Yet Recruiting DMC

• 1 other identifier: EORTC 2124-QLG
• Study Type: observational
• Target: 137
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is a longitudinal observational study that will investigate the feasibility of using mobile devices for the assessment of HRQoL and physical activity in adult cancer patients undergoing treatment. Patients will complete a set of patient reported outcome measures (PROMs), and wear a smartwatch (min. 10 hours per day for one week), at baseline, and at weeks 4, 8 and 12 after treatment start.

Conditions

Diagnosis of Cancer

Outcome Measures

Primary Outcomes (1)

• Assessing the general feasibility of implementing mobile devices for the assessment of HRQoL and PA over a period of 12 weeks in cancer patients undergoing treatment, identifying its major human and operational factors

  General feasibility index (GFI)

  baseline assessment week, week 4, week 8, week 12 and overall

Secondary Outcomes (3)

• To assess the compliance with the Patient Reported Outcome remote assessment

  baseline and weeks 4, 8 and 12

• To assess the compliance with the physical activity remote assessment

  baseline assessment week, week 4, week 8, week 12 and overall

• To assess the patients' user experience related to the Patient Reported Outcome and physical activity remote assessment

  Within 1 month after Week 12

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adult cancer patients prior to the start of a new treatment without restrictions related to gender, cancer site or cancer stage.

You may qualify if:

• Diagnosis of cancer
• Age≥18
• Starting a first or new anticancer treatment within one month following enrolment
• Literacy in the target language
• Ability to understand and fill out questionnaires
• Ability to operate a smartphone
• In possession of a smartphone allowing for an internet connection and willing to use this device to submit data
• Written informed consent
• Life expectancy\>3 months

You may not qualify if:

• Exclusively receiving palliative care
• Start of cancer-related treatment \< 1 week from time of screening
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before enrolment in this study.

Sponsors & Collaborators

• European Organisation for Research and Treatment of Cancer - EORTC: lead

Central Study Contacts

EORTC HQ

CONTACT

+32 2 774 1611; 2124@eortc.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 13, 2026
• First Posted: July 17, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): September 1, 2028
• Last Updated: July 17, 2026

Record last verified: 2026-07